FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Gen Virol / Shedding and interspecies type sero-reactivity of the envelo...
The Journal of general virology1986; 67 ( Pt 11); 2533-2538; doi: 10.1099/0022-1317-67-11-2533

Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus.

Abstract: Two glycopolypeptides with molecular weights 160,000 and 120,000 (gp120) are regularly recognized by human immunodeficiency virus (HIV)-specific antisera in lysates of cells persistently infected with HIV. In the present study, gp120 was characterized as the major envelope glycopolypeptide of HIV. Gp120 was identified as the external viral glycoprotein by radiosequencing and by its presence in purified virus. However gp120 was predominantly shed as a soluble protein into the culture fluid. Furthermore gp120 was precipitated by sera from horses infected with equine infectious anaemia virus (EIAV), but not by sera from uninfected animals. This may indicate conserved epitopes common to the envelopes of HIV and EIAV.
Get Full Text
Publication Date: 1986-11-01 PubMed ID: 2431105DOI: 10.1099/0022-1317-67-11-2533Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Comparative Study
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article is about a study that characterizes gp120 as the major envelope glycopolypeptide of the Human Immunodeficiency Virus (HIV) and identifies a potential commonality between the envelopes of HIV and Equine Infectious Anaemia Virus (EIAV).

Characterization of Glycopolypeptides gp120 in HIV

  • The research focuses on two glycopolypeptides with molecular weights of 160,000 and 120,000 (gp120), specifically identified in cells persistently infected with HIV.
  • Using radiosequencing and other purifying techniques, they identify gp120 as the major envelope glycopolypeptide, which is essentially a component of the external structure of the HIV virus.
  • Interestingly, they found that gp120 was predominantly shed as a solvable protein in the culture fluid, rather than being directly attached to the virus itself.

Common Epitopes in HIV and EIAV

  • The study took an exceptional turn when the researchers found that gp120 was precipitated (made to form a solid) by sera (blood fluid) from horses infected with the EIAV.
  • The uninfected animal sera did not result in the precipitation of the gp120, indicating a possible link or shared characteristic (also known as a conserved epitope) between HIV and EIAV.
  • This suggests that an immunological response triggered against EIAV in horses might also work against HIV in humans.

Implications of the Research

  • This study provides a foundation for understanding the role of gp120 in the behavior and structure of HIV. The identification of gp120 as the major envelope component could further open pathways to understanding the virus’s infection mechanisms and eventual drug targeting
  • The shared epitope between HIV and EIAV, as precipitated by the infected horse sera, potentially opens up a new frontier in HIV therapeutic research, suggesting a cross-species connection.

Cite This Article

APA
Schneider J, Kaaden O, Copeland TD, Oroszlan S, Hunsmann G. (1986). Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus. J Gen Virol, 67 ( Pt 11), 2533-2538. https://doi.org/10.1099/0022-1317-67-11-2533

Publication

The Journal of general virology
ISSN: 0022-1317
NlmUniqueID: 0077340
Country: England
Language: English
Volume: 67 ( Pt 11)
Pages: 2533-2538

Researcher Affiliations

Schneider, J
    Kaaden, O
      Copeland, T D
        Oroszlan, S
          Hunsmann, G

            MeSH Terms

            • Antibodies, Viral / immunology
            • Antigens, Viral / immunology
            • Cross Reactions
            • Culture Media / analysis
            • Epitopes / immunology
            • HIV / immunology
            • HIV Antibodies
            • HIV Envelope Protein gp120
            • Infectious Anemia Virus, Equine / immunology
            • Molecular Weight
            • Retroviridae / classification
            • Retroviridae / immunology
            • Retroviridae Proteins / immunology
            • Species Specificity
            • Visna-maedi virus / immunology

            Citations

            This article has been cited 73 times.
            1. Datta G, Miller NM, Du W, Geiger JD, Chang S, Chen X. Endolysosome Localization of ERα Is Involved in the Protective Effect of 17α-Estradiol against HIV-1 gp120-Induced Neuronal Injury.. J Neurosci 2021 Dec 15;41(50):10365-10381.
              doi: 10.1523/JNEUROSCI.1475-21.2021pubmed: 34764157google scholar: lookup
            2. Umotoy JC, de Taeye SW. Antibody Conjugates for Targeted Therapy Against HIV-1 as an Emerging Tool for HIV-1 Cure.. Front Immunol 2021;12:708806.
              doi: 10.3389/fimmu.2021.708806pubmed: 34276704google scholar: lookup
            3. Sil S, Thangaraj A, Chivero ET, Niu F, Kannan M, Liao K, Silverstein PS, Periyasamy P, Buch S. HIV-1 and drug abuse comorbidity: Lessons learned from the animal models of NeuroHIV.. Neurosci Lett 2021 May 29;754:135863.
              doi: 10.1016/j.neulet.2021.135863pubmed: 33794296google scholar: lookup
            4. Lu M, Ma X, Reichard N, Terry DS, Arthos J, Smith AB 3rd, Sodroski JG, Blanchard SC, Mothes W. Shedding-Resistant HIV-1 Envelope Glycoproteins Adopt Downstream Conformations That Remain Responsive to Conformation-Preferring Ligands.. J Virol 2020 Aug 17;94(17).
              doi: 10.1128/JVI.00597-20pubmed: 32522853google scholar: lookup
            5. Anand AR, Rachel G, Parthasarathy D. HIV Proteins and Endothelial Dysfunction: Implications in Cardiovascular Disease.. Front Cardiovasc Med 2018;5:185.
              doi: 10.3389/fcvm.2018.00185pubmed: 30619892google scholar: lookup
            6. Wenzel ED, Bachis A, Avdoshina V, Taraballi F, Tasciotti E, Mocchetti I. Endocytic Trafficking of HIV gp120 is Mediated by Dynamin and Plays a Role in gp120 Neurotoxicity.. J Neuroimmune Pharmacol 2017 Sep;12(3):492-503.
              doi: 10.1007/s11481-017-9739-4pubmed: 28349243google scholar: lookup
            7. Berth SH, Mesnard-Hoaglin N, Wang B, Kim H, Song Y, Sapar M, Morfini G, Brady ST. HIV Glycoprotein Gp120 Impairs Fast Axonal Transport by Activating Tak1 Signaling Pathways.. ASN Neuro 2016 Dec;8(6).
              doi: 10.1177/1759091416679073pubmed: 27872270google scholar: lookup
            8. Henrick BM, Yao XD, Rosenthal KL. HIV-1 Structural Proteins Serve as PAMPs for TLR2 Heterodimers Significantly Increasing Infection and Innate Immune Activation.. Front Immunol 2015;6:426.
              doi: 10.3389/fimmu.2015.00426pubmed: 26347747google scholar: lookup
            9. Schwalbe B, Schreiber M. Effect of lysine to arginine mutagenesis in the V3 loop of HIV-1 gp120 on viral entry efficiency and neutralization.. PLoS One 2015;10(3):e0119879.
              doi: 10.1371/journal.pone.0119879pubmed: 25785610google scholar: lookup
            10. Berth S, Caicedo HH, Sarma T, Morfini G, Brady ST. Internalization and axonal transport of the HIV glycoprotein gp120.. ASN Neuro 2015 Jan-Feb;7(1).
              doi: 10.1177/1759091414568186pubmed: 25636314google scholar: lookup
            11. Krogh KA, Lyddon E, Thayer SA. HIV-1 Tat activates a RhoA signaling pathway to reduce NMDA-evoked calcium responses in hippocampal neurons via an actin-dependent mechanism.. J Neurochem 2015 Feb;132(3):354-66.
              doi: 10.1111/jnc.12936pubmed: 25156524google scholar: lookup
            12. Raborn ES, Jamerson M, Marciano-Cabral F, Cabral GA. Cannabinoid inhibits HIV-1 Tat-stimulated adhesion of human monocyte-like cells to extracellular matrix proteins.. Life Sci 2014 May 28;104(1-2):15-23.
              doi: 10.1016/j.lfs.2014.04.008pubmed: 24742657google scholar: lookup
            13. Torres-Castro I, Cortés-Rubio CN, Sandoval G, Lamoyi E, Larralde C, Huerta L. Flow cytometry analysis of cell population dynamics and cell cycle during HIV-1 envelope-mediated formation of syncytia in vitro.. In Vitro Cell Dev Biol Anim 2014;50(5):453-63.
              doi: 10.1007/s11626-013-9724-zpubmed: 24442370google scholar: lookup
            14. Palma J, Abood ME, Barbe MF, Benamar K. Functional interaction between HIV-gp120 and opioid system in the preoptic anterior hypothalamus.. Drug Alcohol Depend 2014 Jan 1;134:383-386.
              doi: 10.1016/j.drugalcdep.2013.09.015pubmed: 24120859google scholar: lookup
            15. Jaeger LB, Nath A. Modeling HIV-associated neurocognitive disorders in mice: new approaches in the changing face of HIV neuropathogenesis.. Dis Model Mech 2012 May;5(3):313-22.
              doi: 10.1242/dmm.008763pubmed: 22563057google scholar: lookup
            16. Fanibunda SE, Modi DN, Gokral JS, Bandivdekar AH. HIV gp120 binds to mannose receptor on vaginal epithelial cells and induces production of matrix metalloproteinases.. PLoS One 2011;6(11):e28014.
              doi: 10.1371/journal.pone.0028014pubmed: 22132194google scholar: lookup
            17. Kim HJ, Shin AH, Thayer SA. Activation of cannabinoid type 2 receptors inhibits HIV-1 envelope glycoprotein gp120-induced synapse loss.. Mol Pharmacol 2011 Sep;80(3):357-66.
              doi: 10.1124/mol.111.071647pubmed: 21670103google scholar: lookup
            18. Yang B, Akhter S, Chaudhuri A, Kanmogne GD. HIV-1 gp120 induces cytokine expression, leukocyte adhesion, and transmigration across the blood-brain barrier: modulatory effects of STAT1 signaling.. Microvasc Res 2009 Mar;77(2):212-9.
              doi: 10.1016/j.mvr.2008.11.003pubmed: 19103208google scholar: lookup
            19. Bukreyev A, Yang L, Fricke J, Cheng L, Ward JM, Murphy BR, Collins PL. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes.. J Virol 2008 Dec;82(24):12191-204.
              doi: 10.1128/JVI.01604-08pubmed: 18842713google scholar: lookup
            20. Yang X, Lipchina I, Cocklin S, Chaiken I, Sodroski J. Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization.. J Virol 2006 Nov;80(22):11404-8.
              doi: 10.1128/JVI.01102-06pubmed: 16956933google scholar: lookup
            21. Yang X, Kurteva S, Ren X, Lee S, Sodroski J. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1.. J Virol 2005 Oct;79(19):12132-47.
              doi: 10.1128/JVI.79.19.12132-12147.2005pubmed: 16160141google scholar: lookup
            22. Yang X, Kurteva S, Lee S, Sodroski J. Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.. J Virol 2005 Mar;79(6):3500-8.
              doi: 10.1128/JVI.79.6.3500-3508.2005pubmed: 15731244google scholar: lookup
            23. Zhu P, Chertova E, Bess J Jr, Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.. Proc Natl Acad Sci U S A 2003 Dec 23;100(26):15812-7.
              doi: 10.1073/pnas.2634931100pubmed: 14668432google scholar: lookup
            24. Chertova E, Bess JW Jr, Crise BJ, Sowder II RC, Schaden TM, Hilburn JM, Hoxie JA, Benveniste RE, Lifson JD, Henderson LE, Arthur LO. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.. J Virol 2002 Jun;76(11):5315-25.
              doi: 10.1128/jvi.76.11.5315-5325.2002pubmed: 11991960google scholar: lookup
            25. Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, Schiffner L, Travis B, Kuhmann S, Burton DR, Hu SL, Olson WC, Moore JP. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.. J Virol 2002 Mar;76(6):2606-16.
              doi: 10.1128/jvi.76.6.2606-2616.2002pubmed: 11861826google scholar: lookup
            26. Clayton F, Kotler DP, Kuwada SK, Morgan T, Stepan C, Kuang J, Le J, Fantini J. Gp120-induced Bob/GPR15 activation: a possible cause of human immunodeficiency virus enteropathy.. Am J Pathol 2001 Nov;159(5):1933-9.
              doi: 10.1016/S0002-9440(10)63040-4pubmed: 11696454google scholar: lookup
            27. Albright AV, Martín J, O'Connor M, González-Scarano F. Interactions between HIV-1 gp120, chemokines, and cultured adult microglial cells.. J Neurovirol 2001 Jun;7(3):196-207.
              doi: 10.1080/13550280152403245pubmed: 11517394google scholar: lookup
            28. Stins MF, Shen Y, Huang SH, Gilles F, Kalra VK, Kim KS. Gp120 activates children's brain endothelial cells via CD4.. J Neurovirol 2001 Apr;7(2):125-34.
              doi: 10.1080/13550280152058780pubmed: 11517385google scholar: lookup
            29. Haddrick M, Brown CR, Plishka R, Buckler-White A, Hirsch VM, Ginsberg H. Biologic studies of chimeras of highly and moderately virulent molecular clones of simian immunodeficiency virus SIVsmPBj suggest a critical role for envelope in acute AIDS virus pathogenesis.. J Virol 2001 Jul;75(14):6645-59.
              doi: 10.1128/JVI.75.14.6645-6659.2001pubmed: 11413332google scholar: lookup
            30. Sanders RW, Schiffner L, Master A, Kajumo F, Guo Y, Dragic T, Moore JP, Binley JM. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.. J Virol 2000 Jun;74(11):5091-100.
              doi: 10.1128/jvi.74.11.5091-5100.2000pubmed: 10799583google scholar: lookup
            31. Johnston ER, Radke K. The SU and TM envelope protein subunits of bovine leukemia virus are linked by disulfide bonds, both in cells and in virions.. J Virol 2000 Mar;74(6):2930-5.
              doi: 10.1128/jvi.74.6.2930-2935.2000pubmed: 10684314google scholar: lookup
            32. Mebatsion T, Conzelmann KK. Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein.. Proc Natl Acad Sci U S A 1996 Oct 15;93(21):11366-70.
              doi: 10.1073/pnas.93.21.11366pubmed: 8876141google scholar: lookup
            33. Chirmule N, Pahwa S. Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions.. Microbiol Rev 1996 Jun;60(2):386-406.
              doi: 10.1128/mr.60.2.386-406.1996pubmed: 8801439google scholar: lookup
            34. Langemeier JL, Cook SJ, Cook RF, Rushlow KE, Montelaro RC, Issel CJ. Detection of equine infectious anemia viral RNA in plasma samples from recently infected and long-term inapparent carrier animals by PCR.. J Clin Microbiol 1996 Jun;34(6):1481-7.
              doi: 10.1128/jcm.34.6.1481-1487.1996pubmed: 8735102google scholar: lookup
            35. Willey RL, Shibata R, Freed EO, Cho MW, Martin MA. Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures.. J Virol 1996 Sep;70(9):6431-6.
              doi: 10.1128/JVI.70.9.6431-6436.1996pubmed: 8709276google scholar: lookup
            36. Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide.. J Clin Invest 1996 May 15;97(10):2299-307.
              doi: 10.1172/JCI118672pubmed: 8636410google scholar: lookup
            37. Wyss-Coray T, Masliah E, Toggas SM, Rockenstein EM, Brooker MJ, Lee HS, Mucke L. Dysregulation of signal transduction pathways as a potential mechanism of nervous system alterations in HIV-1 gp120 transgenic mice and humans with HIV-1 encephalitis.. J Clin Invest 1996 Feb 1;97(3):789-98.
              doi: 10.1172/JCI118478pubmed: 8609236google scholar: lookup
            38. Sekigawa I, Koshino K, Hishikawa T, Kaneko H, Takasaki Y, Hashimoto H, Hirose S, Inagaki Y, Yamamoto N. Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120.. J Clin Immunol 1995 Nov;15(6):312-7.
              doi: 10.1007/BF01541321pubmed: 8576317google scholar: lookup
            39. Bujía J, Pitzke P, Wilmes E, Hammer C, Gürtler L. A critical analysis of human immunodeficiency virus transmission using human cartilage allografts.. Eur Arch Otorhinolaryngol 1993;250(1):55-8.
              doi: 10.1007/BF00176950pubmed: 8466751google scholar: lookup
            40. Spies CP, Compans RW. Alternate pathways of secretion of simian immunodeficiency virus envelope glycoproteins.. J Virol 1993 Nov;67(11):6535-41.
              doi: 10.1128/JVI.67.11.6535-6541.1993pubmed: 8411356google scholar: lookup
            41. Spies CP, Ritter GD Jr, Mulligan MJ, Compans RW. Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein alters the conformation of the external domain.. J Virol 1994 Feb;68(2):585-91.
              doi: 10.1128/JVI.68.2.585-591.1994pubmed: 8289362google scholar: lookup
            42. Owens RJ, Burke C, Rose JK. Mutations in the membrane-spanning domain of the human immunodeficiency virus envelope glycoprotein that affect fusion activity.. J Virol 1994 Jan;68(1):570-4.
              doi: 10.1128/JVI.68.1.570-574.1994pubmed: 8254774google scholar: lookup
            43. Bernstein HB, Tucker SP, Hunter E, Schutzbach JS, Compans RW. Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides.. J Virol 1994 Jan;68(1):463-8.
              doi: 10.1128/JVI.68.1.463-468.1994pubmed: 8254757google scholar: lookup
            44. Owens RJ, Rose JK. Cytoplasmic domain requirement for incorporation of a foreign envelope protein into vesicular stomatitis virus.. J Virol 1993 Jan;67(1):360-5.
              doi: 10.1128/JVI.67.1.360-365.1993pubmed: 8093220google scholar: lookup
            45. Atlan H, Gersten MJ, Salk PL, Salk J. Mechanisms of autoimmunity and AIDS: prospects for therapeutic intervention.. Res Immunol 1994 Mar-Apr;145(3):165-83.
              doi: 10.1016/s0923-2494(94)80181-9pubmed: 7991942google scholar: lookup
            46. Geleziunas R, Bour S, Wainberg MA. Human immunodeficiency virus type 1-associated CD4 downmodulation.. Adv Virus Res 1994;44:203-66.
              doi: 10.1016/s0065-3527(08)60330-9pubmed: 7817874google scholar: lookup
            47. Truyen U, Parrish CR, Harder TC, Kaaden OR. There is nothing permanent except change. The emergence of new virus diseases.. Vet Microbiol 1995 Feb;43(2-3):103-22.
              doi: 10.1016/0378-1135(95)92531-fpubmed: 7740750google scholar: lookup
            48. Hogervorst E, de Jong J, van Wijk A, Bakker M, Valk M, Nara P, Goudsmit J. Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.. J Virol 1995 Oct;69(10):6342-51.
              doi: 10.1128/JVI.69.10.6342-6351.1995pubmed: 7666535google scholar: lookup
            49. Moses AV, Bloom FE, Pauza CD, Nelson JA. Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramide-independent mechanism.. Proc Natl Acad Sci U S A 1993 Nov 15;90(22):10474-8.
              doi: 10.1073/pnas.90.22.10474pubmed: 7504264google scholar: lookup
            50. Hui R, Curtis JF, Sumner MT, Shears SB, Glasgow WC, Eling TE. Human immunodeficiency virus type 1 envelope protein does not stimulate either prostaglandin formation or the expression of prostaglandin H synthase in THP-1 human monocytes/macrophages.. J Virol 1995 Dec;69(12):8020-6.
              doi: 10.1128/JVI.69.12.8020-8026.1995pubmed: 7494315google scholar: lookup
            51. Salmon P, Olivier R, Riviere Y, Brisson E, Gluckman JC, Kieny MP, Montagnier L, Klatzmann D. Loss of CD4 membrane expression and CD4 mRNA during acute human immunodeficiency virus replication.. J Exp Med 1988 Dec 1;168(6):1953-69.
              doi: 10.1084/jem.168.6.1953pubmed: 3264318google scholar: lookup
            52. Montefiori DC, Robinson WE Jr, Mitchell WM. Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1.. Proc Natl Acad Sci U S A 1988 Dec;85(23):9248-52.
              doi: 10.1073/pnas.85.23.9248pubmed: 3264072google scholar: lookup
            53. Pyle SW, Dubois GC, Robey WG, Bess JW Jr, Fischinger PJ, Arthur LO. Purification and characterization of the external envelope glycoprotein from two human immunodeficiency virus type 1 variants, HTLV-IIIB and HTLV-IIIRF.. J Virol 1988 Jul;62(7):2258-64.
              doi: 10.1128/JVI.62.7.2258-2264.1988pubmed: 3163739google scholar: lookup
            54. Pinter A, Honnen WJ, Tilley SA, Bona C, Zaghouani H, Gorny MK, Zolla-Pazner S. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1.. J Virol 1989 Jun;63(6):2674-9.
              doi: 10.1128/JVI.63.6.2674-2679.1989pubmed: 2786089google scholar: lookup
            55. Layne SP, Spouge JL, Dembo M. Quantifying the infectivity of human immunodeficiency virus.. Proc Natl Acad Sci U S A 1989 Jun;86(12):4644-8.
              doi: 10.1073/pnas.86.12.4644pubmed: 2734313google scholar: lookup
            56. Gelderblom HR, Ozel M, Pauli G. Morphogenesis and morphology of HIV. Structure-function relations.. Arch Virol 1989;106(1-2):1-13.
              doi: 10.1007/BF01311033pubmed: 2669684google scholar: lookup
            57. Byrn RA, Sekigawa I, Chamow SM, Johnson JS, Gregory TJ, Capon DJ, Groopman JE. Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4.. J Virol 1989 Oct;63(10):4370-5.
              doi: 10.1128/JVI.63.10.4370-4375.1989pubmed: 2550671google scholar: lookup
            58. Berman PW, Riddle L, Nakamura G, Haffar OK, Nunes WM, Skehel P, Byrn R, Groopman J, Matthews T, Gregory T. Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160.. J Virol 1989 Aug;63(8):3489-98.
              doi: 10.1128/JVI.63.8.3489-3498.1989pubmed: 2545918google scholar: lookup
            59. Till MA, Zolla-Pazner S, Gorny MK, Patton JS, Uhr JW, Vitetta ES. Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain.. Proc Natl Acad Sci U S A 1989 Mar;86(6):1987-91.
              doi: 10.1073/pnas.86.6.1987pubmed: 2538826google scholar: lookup
            60. Wahl LM, Corcoran ML, Pyle SW, Arthur LO, Harel-Bellan A, Farrar WL. Human immunodeficiency virus glycoprotein (gp120) induction of monocyte arachidonic acid metabolites and interleukin 1.. Proc Natl Acad Sci U S A 1989 Jan;86(2):621-5.
              doi: 10.1073/pnas.86.2.621pubmed: 2536171google scholar: lookup
            61. Poss ML, Mullins JI, Hoover EA. Posttranslational modifications distinguish the envelope glycoprotein of the immunodeficiency disease-inducing feline leukemia virus retrovirus.. J Virol 1989 Jan;63(1):189-95.
              doi: 10.1128/JVI.63.1.189-195.1989pubmed: 2535725google scholar: lookup
            62. Holschbach C, Schneider J, Geyer H. Glycosylation of the envelope glycoprotein gp130 of simian immunodeficiency virus from sooty mangabey (Cercocebus atys).. Biochem J 1990 May 1;267(3):759-66.
              doi: 10.1042/bj2670759pubmed: 2339985google scholar: lookup
            63. Freed EO, Myers DJ, Risser R. Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.. Proc Natl Acad Sci U S A 1990 Jun;87(12):4650-4.
              doi: 10.1073/pnas.87.12.4650pubmed: 2191297google scholar: lookup
            64. Bosch V, Pawlita M. Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site.. J Virol 1990 May;64(5):2337-44.
              doi: 10.1128/JVI.64.5.2337-2344.1990pubmed: 2182911google scholar: lookup
            65. Rwambo PM, Issel CJ, Adams WV Jr, Hussain KA, Miller M, Montelaro RC. Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection.. Arch Virol 1990;111(3-4):199-212.
              doi: 10.1007/BF01311054pubmed: 2162160google scholar: lookup
            66. Moore JP, McKeating JA, Norton WA, Sattentau QJ. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.. J Virol 1991 Mar;65(3):1133-40.
              doi: 10.1128/JVI.65.3.1133-1140.1991pubmed: 1995942google scholar: lookup
            67. Freed EO, Myers DJ, Risser R. Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain.. J Virol 1991 Jan;65(1):190-4.
              doi: 10.1128/JVI.65.1.190-194.1991pubmed: 1985197google scholar: lookup
            68. McKeating JA, McKnight A, Moore JP. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.. J Virol 1991 Feb;65(2):852-60.
              doi: 10.1128/JVI.65.2.852-860.1991pubmed: 1898972google scholar: lookup
            69. Freed EO, Delwart EL, Buchschacher GL Jr, Panganiban AT. A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity.. Proc Natl Acad Sci U S A 1992 Jan 1;89(1):70-4.
              doi: 10.1073/pnas.89.1.70pubmed: 1729720google scholar: lookup
            70. Manca F, Walker L, Newell A, Celada F, Habeshaw JA, Dalgleish AG. Inhibitory activity of HIV envelope gp120 dominates over its antigenicity for human T cells.. Clin Exp Immunol 1992 Apr;88(1):17-22.
              doi: 10.1111/j.1365-2249.1992.tb03032.xpubmed: 1563103google scholar: lookup
            71. Bernstein HB, Compans RW. Sulfation of the human immunodeficiency virus envelope glycoprotein.. J Virol 1992 Dec;66(12):6953-9.
              doi: 10.1128/JVI.66.12.6953-6959.1992pubmed: 1433500google scholar: lookup
            72. Banda NK, Bernier J, Kurahara DK, Kurrle R, Haigwood N, Sekaly RP, Finkel TH. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis.. J Exp Med 1992 Oct 1;176(4):1099-106.
              doi: 10.1084/jem.176.4.1099pubmed: 1402655google scholar: lookup
            73. Whetstone CA, Sayre KR, Dock NL, VanDerMaaten MJ, Miller JM, Lillehoj E, Alexander SS. Examination of whether persistently indeterminate human immunodeficiency virus type 1 Western immunoblot reactions are due to serological reactivity with bovine immunodeficiency-like virus.. J Clin Microbiol 1992 Apr;30(4):764-70.
              doi: 10.1128/jcm.30.4.764-770.1992pubmed: 1315332google scholar: lookup
            Subscribe to our newsletter
            Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.